CA2299628A1 - Recovery of virus from cell culture using a hypertonic salt solution - Google Patents
Recovery of virus from cell culture using a hypertonic salt solution Download PDFInfo
- Publication number
- CA2299628A1 CA2299628A1 CA002299628A CA2299628A CA2299628A1 CA 2299628 A1 CA2299628 A1 CA 2299628A1 CA 002299628 A CA002299628 A CA 002299628A CA 2299628 A CA2299628 A CA 2299628A CA 2299628 A1 CA2299628 A1 CA 2299628A1
- Authority
- CA
- Canada
- Prior art keywords
- virus
- process according
- harvesting
- culture
- salt solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16651—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A process of harvesting a herpesvirus from a cell culture infected therewith comprises treating said culture with a hypertonic aqueous salt solution to yield a virus suspension, e.g. to give improved yield of virus for live virus vaccine where otherwise cell-disruption might be used to harvest the virus by disrupting virus-infected cells. The harvesting step can be followed e.g. by nuclease treatment, diafiltration and lyophilisation.
Description
RECOVERY OF VIRUS FROM CELL CULTURE USING A HYPERTONIC SALT SOLUTION
Field of the invention:
This invention relates to the production of viruses and to the harvesting of virus preparations from virus-Infected cell cultures, for example for experimental and therapeutic purposes, e.g. for the production of virus vaccines. In particular aspects the invention relates to methods and arrangements for the production of herpesviruses. Other aspects of the invention will be apparent from the description given below.
Background of the invetrtion and Pr-for Art Several methods are known for producing 1 ive virus preparations, e. g.
herpesvirus preparations, for vaccine and other purposes.
For example. US 3.985.615 (Osaka Res Foundation: T Kubo et al) shows production of live attenuated varicella virus for vaccine use by culture comprising passage in guinea pig primary embryonic tissue cells. US
5,024,836 tHerck: 1~1J McAleer et all relates to production of lyophilized vaccine preparations based thereon, DD-209738 (Cent Cerc Bioprep: IV Patrascu) illustrates production of another type of herpesvirus, for use as vaccine against Marek's disease is produced by ta) culturing specific-pathogen-tree chicken embryo cells on dextran microspheres; tb) irroculating the culture at SOX confluence with turkey herpes virus strain FC-126 (clone 1. IIIb): tc) collecting the i nfected cel l s i n SPCA medi um t sucrose. phosphate, gl utasate, bovi ne a1 bumf n fraction V3 when the cytopathic effect is 80x; td) subjecting the suspension to three ultrasonic pulses of 1 minute duration at 2 minute intervals and centrifuging it to recover a first crop of vaccine: te) resuspending the sediaent in SPGA media and repeating step td) to obtain a second crop of vaccine tto increase the vaccine yield by almost 20X): tf) freering the combined vaccines at -100 deg.C prior tv determining the virus titre; and (g) diluting with SP6A medium and freeze drying.
JP06234b59-A (ZH Handai Biseibutsubyo Kenkyukai) describes, in an example. production of herpesviral vaccine on human diploid fibrobl ast MRC-5 cells cultured in MEM medium at 37 deg.C; comprising inoculation of varicella virus 4ka strain seed virus at :a NOI of 0.03 to I~tC-5 cells and culture at 37 deg.C for 2 days. Virus is then suspended in a solution rnntaining 6.4g NaCI, 0.16g KC1, 2.3g Na2HP04..12H2a. 0.16g Kti2P04, 50.Og sucrose, l.Og Na L-glutamate. 2.Og gelatin, 25.Og gelatin hydrolysate and 0,1g EDA-3Na per 1.
EP 0 573 107. US 5.360,736 and US 5.607,852 (Merck: PA Friedman et al) describe processes for production of attenuated varicella zoster virus vaccine, including a process for preparing live, attenuated, cell-free varicella-zoster virus (VZV) vaccine that c~prises: (a) Culturing VZV
infection-susceptible cells, selected from human diploid cells, to confluency in monolayer culture, under conditions of sufficiently high nutrition to achieve a high degree of cell replication. and supplying a non-metabolizable disaccharide; (b) infecting the cells cultured according to step (a) at as close to the point of confluency as possible with as high a multiplicity of infection of YZV-infected cells as practical; tc) maintaining the VZV-infected culture in a state of high nutrition for about 22-96 hours and harvesting at the point of peak infectious VZV production;
(d) washing the VZV-infected culture with a physiologic solution, optionally containing a lysosotaotropic aunt. such as armaonium chloride or chioroquine.
prior to harvesting the VZV infected cells; (e) Harvesting tt~ VZV infected cel l s i rrto a mi nimal vol ume of a stabi 1 i zi ng sol uti on and ei ther di srupti ng the cel l s inmiedi ate! y or freezi ng the cel l s for l ater di srupti on;
(f) Disrupting the 11ZV-infected cells to optimally release cell-associated YZY.
and reuioving cellular debris, to provide a cell-free VZV pr~aration. 'fhe process discloses use of cell densities of up to ca. 500.000 cellslca~ in conventional culture vessels. The process is proposed for mass production of 1 i ve vacci ne . Appropri ate nutri ent medi um for growi ng cel 1 s i n mono! ayer culture in that connection is described as consisting essentially of SFRE-2 medium supplemented with between 0.2 mg/mL and 0.4 mg/mL soybean lipid, the cells being selected from NRC-5 cells, wI-38 cells and Vero cells.
Field of the invention:
This invention relates to the production of viruses and to the harvesting of virus preparations from virus-Infected cell cultures, for example for experimental and therapeutic purposes, e.g. for the production of virus vaccines. In particular aspects the invention relates to methods and arrangements for the production of herpesviruses. Other aspects of the invention will be apparent from the description given below.
Background of the invetrtion and Pr-for Art Several methods are known for producing 1 ive virus preparations, e. g.
herpesvirus preparations, for vaccine and other purposes.
For example. US 3.985.615 (Osaka Res Foundation: T Kubo et al) shows production of live attenuated varicella virus for vaccine use by culture comprising passage in guinea pig primary embryonic tissue cells. US
5,024,836 tHerck: 1~1J McAleer et all relates to production of lyophilized vaccine preparations based thereon, DD-209738 (Cent Cerc Bioprep: IV Patrascu) illustrates production of another type of herpesvirus, for use as vaccine against Marek's disease is produced by ta) culturing specific-pathogen-tree chicken embryo cells on dextran microspheres; tb) irroculating the culture at SOX confluence with turkey herpes virus strain FC-126 (clone 1. IIIb): tc) collecting the i nfected cel l s i n SPCA medi um t sucrose. phosphate, gl utasate, bovi ne a1 bumf n fraction V3 when the cytopathic effect is 80x; td) subjecting the suspension to three ultrasonic pulses of 1 minute duration at 2 minute intervals and centrifuging it to recover a first crop of vaccine: te) resuspending the sediaent in SPGA media and repeating step td) to obtain a second crop of vaccine tto increase the vaccine yield by almost 20X): tf) freering the combined vaccines at -100 deg.C prior tv determining the virus titre; and (g) diluting with SP6A medium and freeze drying.
JP06234b59-A (ZH Handai Biseibutsubyo Kenkyukai) describes, in an example. production of herpesviral vaccine on human diploid fibrobl ast MRC-5 cells cultured in MEM medium at 37 deg.C; comprising inoculation of varicella virus 4ka strain seed virus at :a NOI of 0.03 to I~tC-5 cells and culture at 37 deg.C for 2 days. Virus is then suspended in a solution rnntaining 6.4g NaCI, 0.16g KC1, 2.3g Na2HP04..12H2a. 0.16g Kti2P04, 50.Og sucrose, l.Og Na L-glutamate. 2.Og gelatin, 25.Og gelatin hydrolysate and 0,1g EDA-3Na per 1.
EP 0 573 107. US 5.360,736 and US 5.607,852 (Merck: PA Friedman et al) describe processes for production of attenuated varicella zoster virus vaccine, including a process for preparing live, attenuated, cell-free varicella-zoster virus (VZV) vaccine that c~prises: (a) Culturing VZV
infection-susceptible cells, selected from human diploid cells, to confluency in monolayer culture, under conditions of sufficiently high nutrition to achieve a high degree of cell replication. and supplying a non-metabolizable disaccharide; (b) infecting the cells cultured according to step (a) at as close to the point of confluency as possible with as high a multiplicity of infection of YZV-infected cells as practical; tc) maintaining the VZV-infected culture in a state of high nutrition for about 22-96 hours and harvesting at the point of peak infectious VZV production;
(d) washing the VZV-infected culture with a physiologic solution, optionally containing a lysosotaotropic aunt. such as armaonium chloride or chioroquine.
prior to harvesting the VZV infected cells; (e) Harvesting tt~ VZV infected cel l s i rrto a mi nimal vol ume of a stabi 1 i zi ng sol uti on and ei ther di srupti ng the cel l s inmiedi ate! y or freezi ng the cel l s for l ater di srupti on;
(f) Disrupting the 11ZV-infected cells to optimally release cell-associated YZY.
and reuioving cellular debris, to provide a cell-free VZV pr~aration. 'fhe process discloses use of cell densities of up to ca. 500.000 cellslca~ in conventional culture vessels. The process is proposed for mass production of 1 i ve vacci ne . Appropri ate nutri ent medi um for growi ng cel 1 s i n mono! ayer culture in that connection is described as consisting essentially of SFRE-2 medium supplemented with between 0.2 mg/mL and 0.4 mg/mL soybean lipid, the cells being selected from NRC-5 cells, wI-38 cells and Vero cells.
3 ( Immlr~ol ogy Ltd ; SC ingl i s et al ) and WO 94!21807 ( Cantab Pharmaceuticals Research: Inglis et a1) are illustrative of the provision of ri nant cel l s and cul tune methods for produci ng genets cal 1 y di sabi ed herpesvirus such as herpes simplex virus for vaccine purposes.
It remains desriable to provide methods for treatment of virus-contai ni ng preparati ons , capabl a of contra buts ng to the manufacture of vi rus preparations in good yield and purity.
~tRY AND DESCR.I~"TION OF THE_ INVENTION
According to one aspect of the present invention, a cell culture infected with a herpesvirus can be treated to yield a virus suspension by a harvesting incubation with a hypertonic aqueous salt solution. The salt solution can be contacted with the cell culture tv yield a liquid containing useful virus content and a much reduced content of cells or cell debris by comparison with (for example) the product of ultrasonic disruption. This process can for exan~l a be parts cut art y appl i cabl a to gi ve an improved yi al d of virus for the manufacture of live virus vaccine in a case where otherwise a cell-disruption step might be used to harvest virus by disrupting virus-infected cells of a virus-producing cell culture.
Hany pharmaceutically acceptable salts are suitable and acceptable for this purpose, for example sodium chloride, sodium sulphate, potassium chloride, and others. Preferably the salt solution can comprise sodium chlon de at for exempla about D.8 to D.9 M concentration or a~ve. If I5 sodium sulphate is used, concentration can preferably be about 0.4H or above. Other salts can be used, if desired at similar osmolarity or ionic strength to the concentrations indicated above. The virus can often stand up to iM or 2H salt concentration but in each case, it is preferred not to go too far above the indicated concentration, so as to avoid excessive uptake of protein into the saline liquid. Suffering and other constituents can be chosen suitably in accordance with normal practice for handling the viruses concerned.
The harvesting incubation can be carried out with gentle agitation, and preferably is carried out in such a way as to involve no or ninio~al cell disruption. The cell culture to be treated to the harvesting incubation can be for exan~rle a monolayer culture or a microcarrier culture or a roller-bottle culture.
Tt~e harvesting salt solution can be buffered and maintained at a pH
and temperature in themselves suitable for the culture of the virus-infected cells, e.g, about pH 7 and advantageously about 34 deg.C. for herpes simplex virus.
Contact time between the cultured cells and the harvesting liquid is not specially critical and can for example be in the range of about 2-24 hours. It has been found in connection with certain examples that for example about 4 hours contact time is preferable because it can offer good yield with acceptably low levels of cellular protein.
After contact between the cultured infected cells and the harvesting liquid, the liquid containing the harvested virus particles. can be separated by decantation or any other suitable method; the cultured cells themselves can be allowed to remain attached to the surface on which they were cultured, and can be discarded after the separation of the harvesting liquid.
The harvesting liquid can then if desired be treated by filtration and/or centrifugation to remove residual~cells.
Desirably, the harvested preparation can be diluted or dia-filtered to approximately isotonic concentration. e.g. about 138 mM in sodium chloride.
I5 According to a further aspect of the invention, the virus preparation harvested in this way can be treated with nuclease enzyme to reduce any content of co~rtaminating nucleic acid to acceptable levels.
The diluted liquid can for exan~le be treated with Benzonase (TM) nuclease enzyme, to degrade free nucleic acids (ia~ortantly DNA, and usually al so RNA) at up to about 50 uni tsJm1 i n the presence of about 2-10 mt~!
magnesium ion, either for up to about 1 hour at from about 4 deg.C to room temperature.
The 1 evel of nucl ease enzyme and other protei n can then be reduced for example by dia-filtration against a suitable forn~rlation buffer, through a membrane with a virus-retaining, e.g. 500kD, exclusion limit.
After these treatments the harvested virus can be transferred to a desired carrier liquid and frozen, lyophilised or otherwise stabilised in any suitable manner.
Processes accordi ng to exanpl es of the i nventi on can offer parti cut ar advantage in connection with highly:,cel1-associated viruses, i.e. those viruses having a particularly high degree of cell association in culture, for example herpes simplex virus type 2 (HSY-2), pseudorabies virus (PRY?.
turkey herpesvirus and varicella zoster virus (VZV). With certain herpesviruses and culture conditions (e. g. with herpes simplex virus type 1 (HSV-1)) there can be a substantial spontaneous release of virus from the infected cells into the cell culture liquid, so that application of a process according to an example of the present inve~ion can sometimes here be unnecessary and accordingly such examples of the invention are less preferred.
The invention can be applied with any appropriate adaptations of detail as will be readily accessible to those skilled in the art, to herpesviruses of various types, including for example wild-type herpes simpl ex vi rus and genetical ly di sabTed herpes vi ruses such as herpes simpl ex virus. and for example other herpes viruses as mentioned in the documents cited herein.
The virus preparations obtained by the use of processing steps as described herein can be further processed and made part of pharmaceutical compositions e.g. with per-se cronventional ingredients of virus vaccines.
The inverrtion is further described and illustrated by the following non-limitative example.
EXAMFLE~
z0 A process accordi ng to an exampl a of :the i rnrenti on, for harvesti ng and purl fyi ng vi rus parti cl es , can hake use of a cul Lure of hero cel l s i nfected with Hsv-2, grown essentially 1n known manner in conventional culture medium corrtained in roller bottles at about 100m1 of medium per bottle. The culture medium, cell type and culture conditions can be for example as Z5 follows:
The Yero cells can be passaged at 2 x 10"7 cells per roller bottle.
Culture can be carried out using DMEM medium with 4.5 g/l glucose without sodium pyruvate and with Glutamax-I tTM) tl-alanyl-L-glutalnine). 862 mgll.
Incubation can be carried out for example at about 37 deg.C and for abut 30 120 tmurs t5 days) . Confluent cell cultures can then be infected with HSY-at a multiplicity of infection of about 0.01, by dilut~tng the virus in DMEM
to the level where 1 m1 is added to each roller bottle which is then returned to the roller-incubation apparatus at about 34-37 deg.C. When - cytopathic effect is observed to be 80~100x, e.g. 65-72 hours after 35 infection. the roller bottles can be treated as ready for virus harvest.
The culture mediwn can be decanted from each bottle and replaced by 10m1 per bottle of a buffered sodium chloride solution tabout 0.8-0.9M) containing 0.O1M sodium citrate pH 7Ø The cells in the roller bottle in contact with this buffered sodium chloride solution can be rolled and 40 incubated at about 34 deg.C for about 4 hours.
*rB
The cul tured cell s themsel vas i n the roi i er botti a can 1 argel y remai n attached to the bottle surface and can be discarded after separation of the liquid containing the harvested virus particles.
The 1 i qui d i n the bottl e, co~ri si ng the buffered sal i ne and materi a7 from the cell culture in suspension.' including virus, can be removed by pipette and centrifuged at about 3000 rpm in a Sorvall RT6000 (TM) centrifuge for about 10 minutes (e.g. at RCFmax about 1876). The cells in the pellet. and those remaining in the bottle, are discarded (under appropriate virus-containment conditions) and the supernatant is taken by pipette to the next step, which can be continuous flow centrifugation. Pre~
filtration can be carried out with a 0.8 micron filter. The supernatant liquid from centrifugation can be diluted or diafiltered to a final concentration (in respect of sodium ion) of 138mM.
The diluted liquid can then be treated with 8enzonase (Th? nuclease enzyme, to degrade free nucleic acids (importantly the enzyme used has DNase activity. and usually also, like Benzonase (TAI). will have RNase activity) at up to about 50 unitsJml in the presence of about 2-10 mM magnesium ion.
e.g. for up to about 1 hour at a temperatare from about 4 deg.C up to room te~erature.
The reaction liquid can then be subjected to tangential cross~flow filtration (diafiltration) using a filter/menbrane with a 500kD exclusion limit in a Filtron (TM) or other tangential crossflow device, using a recirculation rate of 1000 ml/min. a filtrate rate of 100 m1/min, and a backflush of 100 ml sodium citrate O.O1M pH 7.25 containing 138 mhi sodium chloride.
The retentate from the cross-flow ultrafiltration step can then be treated by diafiltration against 5-10 volumes~of citratelsaline buffer to reduce the amount of noel ease enzyme, and the retentate i s fi nal l y suh jetted to 0.2 micron (sterilising) filtration optionally preceded by filtration with a filter of from about 0.45 micron to 5 micron. using the same buffer again, after making the liquid containing the virus preparation up to ZO
mg/ml in a suitable stabilising protein. preferably human serum albumin at about 20 mg/ml. It can be useful to prewash the filters with a liquid co~rtaini ng the same stabi 1 i si ng protei n i n the same buffer, before usi ng the filters to treat the virus preparation.
The resulting product can be obtained as a suspension of virus particles in saline buffer and stabilising protein. in which the level of residual DNA can be satisfactorily low.
The yield from such a process has been found to be usefully good by comparison with a process involving ultrasonic cell disruption to liberate vi rus parti cl es, fol 1 owed by separati on of vi rue parti cl es from cel 1 debri s .
The i nventi on can be very useful 1 y appl i ed, for exampl a i n a preferred embodiment carried out according to the example described above, to the culture and harvesting of genetically disabled HSV-2 virus for vaccine use, which virus has a deletion in respect of the gH gene essential Por production of infectious new virus particles, and is cu7turable on a cell 1 i rte whi ch i s based on Yero cel 1 s whi ch have been made recombinant and ab1 a to express the viral gH gene which is missing from the viral genome, e.g.
as described in specifications WO 92/05263 and iJ0 94/21807 (and see also A
Forrester et al. J Yiral 66 (1992) 341-348, also H ~ Farrell et al, J llirol 68 (1994) 927-932) and C McLean et al. J Infect Dis 170 (1994) 1100-1109).
It can also be preferable, according to convenience, to culture the cells and viruses on various forms of microcarriers in per-se known manner.
instead of in roller bottles.
The present invention and disclosure extend to the methods and compositions and the resulting products as described herein, and to modifications and variations of the features mentioned and described herein, i ncl udi ng combi nati one and subcombi nati one thereof , and the docuo~er~ts ci ted herei n are hereby i ncorporated by reference in thei r errti rety for all purposes.
It remains desriable to provide methods for treatment of virus-contai ni ng preparati ons , capabl a of contra buts ng to the manufacture of vi rus preparations in good yield and purity.
~tRY AND DESCR.I~"TION OF THE_ INVENTION
According to one aspect of the present invention, a cell culture infected with a herpesvirus can be treated to yield a virus suspension by a harvesting incubation with a hypertonic aqueous salt solution. The salt solution can be contacted with the cell culture tv yield a liquid containing useful virus content and a much reduced content of cells or cell debris by comparison with (for example) the product of ultrasonic disruption. This process can for exan~l a be parts cut art y appl i cabl a to gi ve an improved yi al d of virus for the manufacture of live virus vaccine in a case where otherwise a cell-disruption step might be used to harvest virus by disrupting virus-infected cells of a virus-producing cell culture.
Hany pharmaceutically acceptable salts are suitable and acceptable for this purpose, for example sodium chloride, sodium sulphate, potassium chloride, and others. Preferably the salt solution can comprise sodium chlon de at for exempla about D.8 to D.9 M concentration or a~ve. If I5 sodium sulphate is used, concentration can preferably be about 0.4H or above. Other salts can be used, if desired at similar osmolarity or ionic strength to the concentrations indicated above. The virus can often stand up to iM or 2H salt concentration but in each case, it is preferred not to go too far above the indicated concentration, so as to avoid excessive uptake of protein into the saline liquid. Suffering and other constituents can be chosen suitably in accordance with normal practice for handling the viruses concerned.
The harvesting incubation can be carried out with gentle agitation, and preferably is carried out in such a way as to involve no or ninio~al cell disruption. The cell culture to be treated to the harvesting incubation can be for exan~rle a monolayer culture or a microcarrier culture or a roller-bottle culture.
Tt~e harvesting salt solution can be buffered and maintained at a pH
and temperature in themselves suitable for the culture of the virus-infected cells, e.g, about pH 7 and advantageously about 34 deg.C. for herpes simplex virus.
Contact time between the cultured cells and the harvesting liquid is not specially critical and can for example be in the range of about 2-24 hours. It has been found in connection with certain examples that for example about 4 hours contact time is preferable because it can offer good yield with acceptably low levels of cellular protein.
After contact between the cultured infected cells and the harvesting liquid, the liquid containing the harvested virus particles. can be separated by decantation or any other suitable method; the cultured cells themselves can be allowed to remain attached to the surface on which they were cultured, and can be discarded after the separation of the harvesting liquid.
The harvesting liquid can then if desired be treated by filtration and/or centrifugation to remove residual~cells.
Desirably, the harvested preparation can be diluted or dia-filtered to approximately isotonic concentration. e.g. about 138 mM in sodium chloride.
I5 According to a further aspect of the invention, the virus preparation harvested in this way can be treated with nuclease enzyme to reduce any content of co~rtaminating nucleic acid to acceptable levels.
The diluted liquid can for exan~le be treated with Benzonase (TM) nuclease enzyme, to degrade free nucleic acids (ia~ortantly DNA, and usually al so RNA) at up to about 50 uni tsJm1 i n the presence of about 2-10 mt~!
magnesium ion, either for up to about 1 hour at from about 4 deg.C to room temperature.
The 1 evel of nucl ease enzyme and other protei n can then be reduced for example by dia-filtration against a suitable forn~rlation buffer, through a membrane with a virus-retaining, e.g. 500kD, exclusion limit.
After these treatments the harvested virus can be transferred to a desired carrier liquid and frozen, lyophilised or otherwise stabilised in any suitable manner.
Processes accordi ng to exanpl es of the i nventi on can offer parti cut ar advantage in connection with highly:,cel1-associated viruses, i.e. those viruses having a particularly high degree of cell association in culture, for example herpes simplex virus type 2 (HSY-2), pseudorabies virus (PRY?.
turkey herpesvirus and varicella zoster virus (VZV). With certain herpesviruses and culture conditions (e. g. with herpes simplex virus type 1 (HSV-1)) there can be a substantial spontaneous release of virus from the infected cells into the cell culture liquid, so that application of a process according to an example of the present inve~ion can sometimes here be unnecessary and accordingly such examples of the invention are less preferred.
The invention can be applied with any appropriate adaptations of detail as will be readily accessible to those skilled in the art, to herpesviruses of various types, including for example wild-type herpes simpl ex vi rus and genetical ly di sabTed herpes vi ruses such as herpes simpl ex virus. and for example other herpes viruses as mentioned in the documents cited herein.
The virus preparations obtained by the use of processing steps as described herein can be further processed and made part of pharmaceutical compositions e.g. with per-se cronventional ingredients of virus vaccines.
The inverrtion is further described and illustrated by the following non-limitative example.
EXAMFLE~
z0 A process accordi ng to an exampl a of :the i rnrenti on, for harvesti ng and purl fyi ng vi rus parti cl es , can hake use of a cul Lure of hero cel l s i nfected with Hsv-2, grown essentially 1n known manner in conventional culture medium corrtained in roller bottles at about 100m1 of medium per bottle. The culture medium, cell type and culture conditions can be for example as Z5 follows:
The Yero cells can be passaged at 2 x 10"7 cells per roller bottle.
Culture can be carried out using DMEM medium with 4.5 g/l glucose without sodium pyruvate and with Glutamax-I tTM) tl-alanyl-L-glutalnine). 862 mgll.
Incubation can be carried out for example at about 37 deg.C and for abut 30 120 tmurs t5 days) . Confluent cell cultures can then be infected with HSY-at a multiplicity of infection of about 0.01, by dilut~tng the virus in DMEM
to the level where 1 m1 is added to each roller bottle which is then returned to the roller-incubation apparatus at about 34-37 deg.C. When - cytopathic effect is observed to be 80~100x, e.g. 65-72 hours after 35 infection. the roller bottles can be treated as ready for virus harvest.
The culture mediwn can be decanted from each bottle and replaced by 10m1 per bottle of a buffered sodium chloride solution tabout 0.8-0.9M) containing 0.O1M sodium citrate pH 7Ø The cells in the roller bottle in contact with this buffered sodium chloride solution can be rolled and 40 incubated at about 34 deg.C for about 4 hours.
*rB
The cul tured cell s themsel vas i n the roi i er botti a can 1 argel y remai n attached to the bottle surface and can be discarded after separation of the liquid containing the harvested virus particles.
The 1 i qui d i n the bottl e, co~ri si ng the buffered sal i ne and materi a7 from the cell culture in suspension.' including virus, can be removed by pipette and centrifuged at about 3000 rpm in a Sorvall RT6000 (TM) centrifuge for about 10 minutes (e.g. at RCFmax about 1876). The cells in the pellet. and those remaining in the bottle, are discarded (under appropriate virus-containment conditions) and the supernatant is taken by pipette to the next step, which can be continuous flow centrifugation. Pre~
filtration can be carried out with a 0.8 micron filter. The supernatant liquid from centrifugation can be diluted or diafiltered to a final concentration (in respect of sodium ion) of 138mM.
The diluted liquid can then be treated with 8enzonase (Th? nuclease enzyme, to degrade free nucleic acids (importantly the enzyme used has DNase activity. and usually also, like Benzonase (TAI). will have RNase activity) at up to about 50 unitsJml in the presence of about 2-10 mM magnesium ion.
e.g. for up to about 1 hour at a temperatare from about 4 deg.C up to room te~erature.
The reaction liquid can then be subjected to tangential cross~flow filtration (diafiltration) using a filter/menbrane with a 500kD exclusion limit in a Filtron (TM) or other tangential crossflow device, using a recirculation rate of 1000 ml/min. a filtrate rate of 100 m1/min, and a backflush of 100 ml sodium citrate O.O1M pH 7.25 containing 138 mhi sodium chloride.
The retentate from the cross-flow ultrafiltration step can then be treated by diafiltration against 5-10 volumes~of citratelsaline buffer to reduce the amount of noel ease enzyme, and the retentate i s fi nal l y suh jetted to 0.2 micron (sterilising) filtration optionally preceded by filtration with a filter of from about 0.45 micron to 5 micron. using the same buffer again, after making the liquid containing the virus preparation up to ZO
mg/ml in a suitable stabilising protein. preferably human serum albumin at about 20 mg/ml. It can be useful to prewash the filters with a liquid co~rtaini ng the same stabi 1 i si ng protei n i n the same buffer, before usi ng the filters to treat the virus preparation.
The resulting product can be obtained as a suspension of virus particles in saline buffer and stabilising protein. in which the level of residual DNA can be satisfactorily low.
The yield from such a process has been found to be usefully good by comparison with a process involving ultrasonic cell disruption to liberate vi rus parti cl es, fol 1 owed by separati on of vi rue parti cl es from cel 1 debri s .
The i nventi on can be very useful 1 y appl i ed, for exampl a i n a preferred embodiment carried out according to the example described above, to the culture and harvesting of genetically disabled HSV-2 virus for vaccine use, which virus has a deletion in respect of the gH gene essential Por production of infectious new virus particles, and is cu7turable on a cell 1 i rte whi ch i s based on Yero cel 1 s whi ch have been made recombinant and ab1 a to express the viral gH gene which is missing from the viral genome, e.g.
as described in specifications WO 92/05263 and iJ0 94/21807 (and see also A
Forrester et al. J Yiral 66 (1992) 341-348, also H ~ Farrell et al, J llirol 68 (1994) 927-932) and C McLean et al. J Infect Dis 170 (1994) 1100-1109).
It can also be preferable, according to convenience, to culture the cells and viruses on various forms of microcarriers in per-se known manner.
instead of in roller bottles.
The present invention and disclosure extend to the methods and compositions and the resulting products as described herein, and to modifications and variations of the features mentioned and described herein, i ncl udi ng combi nati one and subcombi nati one thereof , and the docuo~er~ts ci ted herei n are hereby i ncorporated by reference in thei r errti rety for all purposes.
Claims (9)
1: A process of harvesting a herpesvirus from a cell culture infected therewith, which comprises treating said culture with a hypertonic aqueous salt solution to yield a virus suspension.
2: A process according to claim 1. wherein the virus suspension is further treated to formulate it as a pharmaceutical preparation suitable for use as a virus vaccine.
3: A process according to claim 1 or 2, wherein the salt comprises sodium chloride at about 0.8 M concentration or above.
4: A process according to claim 1, 2 or 3 wherein the harvesting salt solution is buffered at a pH about 7 and temperature about 34 deg.C. for the harvesting of herpes simplex virus.
5: A process according to any of claims 1-4 wherein the harvested preparation is then diluted or dia-filtered to approximately isotonic concentration.
6: A process according to any of claims 1-5 wherein the harvested virus preparation is treated with nuclease enzyme.
7: A process according to claim 6 wherein the preparation after nuclease treatment is dia-filtered against a formulation buffer. through a membrane with a virus-retaining exclusion limit.
8: A process according to any preceding claim wherein the harvested virus, after transfer to a desired carrier liquid, is frozen, lyophilised or otherwise stabilised.
9: A process according to claim 1, wherein the virus comprises herpes simplex virus type 2 (HSV-2), pseudorahies virus (PRV), turkey herpesvirus or varicella zoster virus (VZV).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9716611.0A GB9716611D0 (en) | 1997-08-07 | 1997-08-07 | Virus preparations and methods |
| GB9716611.0 | 1997-08-07 | ||
| PCT/GB1998/002387 WO1999007834A1 (en) | 1997-08-07 | 1998-08-07 | Recovery of virus from cell culture using a hypertonic salt solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2299628A1 true CA2299628A1 (en) | 1999-02-18 |
Family
ID=10817061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002299628A Abandoned CA2299628A1 (en) | 1997-08-07 | 1998-08-07 | Recovery of virus from cell culture using a hypertonic salt solution |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1002055B2 (en) |
| JP (2) | JP2001512675A (en) |
| AT (1) | ATE270325T1 (en) |
| AU (1) | AU8737298A (en) |
| CA (1) | CA2299628A1 (en) |
| DE (1) | DE69824856T2 (en) |
| DK (1) | DK1002055T3 (en) |
| ES (1) | ES2224422T3 (en) |
| GB (1) | GB9716611D0 (en) |
| PT (1) | PT1002055E (en) |
| WO (1) | WO1999007834A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4790984B2 (en) | 2001-09-06 | 2011-10-12 | アルファヴァックス，インコーポレイテッド | Alphavirus replicon vector system |
| ES2630222T3 (en) * | 2002-12-13 | 2017-08-18 | Alphavax, Inc. | Alpha Particles and Preparation Methods |
| MXPA05010007A (en) | 2003-03-20 | 2006-03-10 | Alphavax Inc | Improved alphavirus replicons and helper constructs. |
| US7270990B2 (en) | 2003-06-20 | 2007-09-18 | Microbix Biosystems, Inc. | Virus production |
| CN100398642C (en) * | 2003-06-20 | 2008-07-02 | 迈克必斯生物系统公司 | Improvements in virus production |
| EP1651666B1 (en) | 2003-07-11 | 2009-05-27 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
| ES2588906T3 (en) | 2007-06-21 | 2016-11-07 | Alphavax, Inc. | Cassettes without promoter for the expression of alphavirus structural proteins |
| JP5980947B2 (en) | 2012-11-22 | 2016-08-31 | 旭化成メディカル株式会社 | Production method of parvovirus with high infectivity |
| CN104250639A (en) * | 2013-06-28 | 2014-12-31 | 北京奥源和力生物技术有限公司 | Method for harvesting and producing viruses |
| US10808227B2 (en) | 2015-11-06 | 2020-10-20 | Asahi Kasei Medical Co., Ltd. | Method for producing parvovirus having high infectivity titer and high purity |
| US10626376B2 (en) | 2016-11-14 | 2020-04-21 | St. Jude Children's Research Hospital | Method for isolating and purifying adeno-associated virus particles using salt |
| IL299723A (en) * | 2020-07-10 | 2023-03-01 | Boehringer Ingelheim Int | Process for producing a purified rhabdovirus from cell culture |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204257A (en) * | 1991-04-29 | 1993-04-20 | Autogen Instruments, Inc. | Method of recovering bacteriophage |
| SK279387B6 (en) * | 1992-06-04 | 1998-10-07 | Merck & Co. | Method of producing alive attenuated varicella zoster virus vaccine, method of cell cultivation and cultivating medium for cell cultivation |
-
1997
- 1997-08-07 GB GBGB9716611.0A patent/GB9716611D0/en active Pending
-
1998
- 1998-08-07 PT PT98938765T patent/PT1002055E/en unknown
- 1998-08-07 ES ES98938765T patent/ES2224422T3/en not_active Expired - Lifetime
- 1998-08-07 DK DK98938765T patent/DK1002055T3/en active
- 1998-08-07 AU AU87372/98A patent/AU8737298A/en not_active Abandoned
- 1998-08-07 CA CA002299628A patent/CA2299628A1/en not_active Abandoned
- 1998-08-07 JP JP2000506319A patent/JP2001512675A/en active Pending
- 1998-08-07 DE DE69824856T patent/DE69824856T2/en not_active Expired - Lifetime
- 1998-08-07 AT AT98938765T patent/ATE270325T1/en not_active IP Right Cessation
- 1998-08-07 EP EP98938765A patent/EP1002055B2/en not_active Expired - Lifetime
- 1998-08-07 WO PCT/GB1998/002387 patent/WO1999007834A1/en active IP Right Grant
-
2009
- 2009-09-14 JP JP2009212117A patent/JP2009297036A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ATE270325T1 (en) | 2004-07-15 |
| EP1002055B1 (en) | 2004-06-30 |
| DK1002055T3 (en) | 2004-10-25 |
| GB9716611D0 (en) | 1997-10-08 |
| EP1002055B2 (en) | 2010-04-14 |
| EP1002055A1 (en) | 2000-05-24 |
| AU8737298A (en) | 1999-03-01 |
| JP2009297036A (en) | 2009-12-24 |
| DE69824856D1 (en) | 2004-08-05 |
| ES2224422T3 (en) | 2005-03-01 |
| JP2001512675A (en) | 2001-08-28 |
| PT1002055E (en) | 2004-10-29 |
| WO1999007834A1 (en) | 1999-02-18 |
| DE69824856T2 (en) | 2005-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1062325B1 (en) | Purification of virus preparations | |
| JP2009297036A (en) | Method for recovering virus from cell culture using hypertonic salt solution | |
| JPH06234659A (en) | Stabilized live vaccine | |
| RU2146289C1 (en) | Strain of human embryo lung fibroblast diploid cells used for virus culturing | |
| US20090042273A1 (en) | Recovery of virus from cell culture using hypertonic salt solution | |
| US4049494A (en) | Vaccine production process | |
| DE69730993T2 (en) | ASSEMBLY-DEFICIENT HERPESVIRUS AS VACCINE | |
| CN113874495A (en) | Method for producing virus and harvesting solution composition | |
| AU780112B2 (en) | Recovery of virus from cell culture using a hypertonic salt solution | |
| KR20010072556A (en) | Medium and method for viral propagation and growth | |
| AU2005322521A1 (en) | Virus preparations and methods | |
| MXPA00001260A (en) | Recovery of virus from cell culture using a hypertonic salt solution | |
| AU2002302069B2 (en) | Virus preparations and methods | |
| MXPA00008535A (en) | Virus preparations and methods | |
| MXPA06000056A (en) | Virus preparations and methods | |
| CA1216234A (en) | Preparation of modified strains of bovine diarrhoea virus and vaccines containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |